Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
Globe Newswire•07/10/2026•16:05 ET
0
Key Highlights
- ➤Alector will host an October 13 virtual webinar on its ABC-enabled pipeline
- ➤AL137 targets pyroglutamate Aβ with enhanced brain exposure and monthly subcutaneous dosing
- ➤AL164, AL062 and ADP065 target tau, α-synuclein and NLRP3, respectively
- ➤Preclinical data will demonstrate target reduction across multiple brain regions
- ➤ABC-enabled siRNA programs are designed for once-quarterly subcutaneous dosing
Agenda to feature progress for AL137, its lead anti-amyloid beta antibody; AL164, its tau siRNA program; and AL062, its alpha-synuclein siRNA program
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced management will host a virtual event to discuss the company's wholly owned ABC blood-brain barrier platform and programs in its ABC-enabled pipeline.
Get started
Create a free account to read the full story.